Q3 2019
The company is also gradually diversifying its business, with 20% of the expected value of new contracts coming from the non-diabetes business.
Despite some wins across its various business efforts, Fitbit's mounting losses provide some insight as to why the company was looking to sell.
The deals include big names like Philips, long-time startup players like Mango Health and a dose of private equity.